Publications dans lesquelles il/elle collabore avec ANTONIA ARANEGA JIMÉNEZ (52)

2016

  1. Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results

    Oxidative Medicine and Cellular Longevity, Vol. 2016

  2. Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells

    Archives of Medical Science, Vol. 12, Núm. 5, pp. 919-927

2015

  1. Computer tools and collaborative translational research in the life sciences: The further advance of genomics and proteomics

    European Journal of Anatomy, Vol. 19, Núm. 2, pp. 131-137

2014

  1. Cancer stem cells and their implication in breast cancer

    European Journal of Clinical Investigation, Vol. 44, Núm. 7, pp. 678-687

  2. Exosomes Derived from Breast Cancer Cells, Small Trojan Horses?

    Journal of Mammary Gland Biology and Neoplasia, Vol. 19, Núm. 3-4, pp. 303-313

  3. Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo

    European Journal of Medicinal Chemistry, Vol. 79, pp. 1-12

2013

  1. Antitumor properties of natural compounds and related molecules

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 8, Núm. 3, pp. 203-215

  2. Colon cancer therapy: Recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 13, Núm. 8, pp. 1204-1216

  3. Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance

    Cancer Chemotherapy and Pharmacology, Vol. 71, Núm. 2, pp. 537-541

  4. Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing

    BioMed Research International, Vol. 2013

2012

  1. Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells

    Biomedicine and Pharmacotherapy, Vol. 66, Núm. 7, pp. 563-567

  2. How is gene transfection able to improve current chemotherapy? The role of combined therapy in cancer treatment

    Current Medicinal Chemistry, Vol. 19, Núm. 12, pp. 1870-1888

  3. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

    Journal of Translational Medicine, Vol. 10, Núm. 1

  4. New gene therapy strategies for cancer treatment: A review of recent patents

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 7, Núm. 3, pp. 297-312

  5. The selective cytotoxic activity in breast cancer cells by an anthranilic alcohol-derived acyclic 5-fluorouracil O,N-acetal is mediated by endoplasmic reticulum stress-induced apoptosis

    European Journal of Medicinal Chemistry, Vol. 50, pp. 376-382

  6. Treatment of heart disease: Use of transdifferentiation methodology for reprogramming adult stem cells

    Stem Cells and Cancer Stem Cells, Volume 2: Stem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury: Volume 2 (Springer Netherlands), pp. 169-183

2011

  1. Anticancer activity and cDNA microarray studies of a (RS)-1,2,3,5- tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine, and an acyclic (RS)-O,N-acetalic 6-chloro-7H-purine

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 9, pp. 3802-3809

  2. Development of patents and clinical trials on regenerative therapy: Gene therapy

    Recent Patents on Regenerative Medicine, Vol. 1, Núm. 2, pp. 182-194

  3. Nanomedicine: Application areas and development prospects

    International Journal of Molecular Sciences, Vol. 12, Núm. 5, pp. 3303-3321

  4. New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1- benzoxazepin-3-yl]-9H-purine

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 1, pp. 249-258